Finance

Lists
TRDA:NASDAQ
Entrada Therapeutics Inc
US$ ५.०९
-१.५५%
(-०.०८०) 1D
नोभेम्बर १३, १६:००:०० GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TRDA...
Open
US$ ५.१७
High
US$ ५.२५
Low
US$ ४.९१
Mkt. cap
१९.९३ करोड
Avg. vol.
४.५२ लाख
Volume
७.९२ लाख
52-wk high
US$ १६.४५
52-wk low
US$ ४.११
EPS
-US$ ३.८४
Beta
-०.१९
Shares outstanding
३.९२ करोड
No. of employees
१५२
Open
US$ ५.१७
High
US$ ५.२५
Low
US$ ४.९१
Mkt. cap
१९.९३ करोड
Avg. vol.
४.५२ लाख
Volume
७.९२ लाख
52-wk high
US$ १६.४५
52-wk low
US$ ४.११
EPS
-US$ ३.८४
Beta
-०.१९
Shares outstanding
३.९२ करोड
No. of employees
१५२
News stories
From web sources and news partners
The Motley Fool
The Motley Fool
·
६ घण्टा पहिले
This Dividend King Yields 5 Times the S&P 500. Is It a Buy Now?
About Entrada Therapeutics Inc
CEO-
Employees१५२
Founded२०१६
Headquartersबोस्टन, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Analyst ratings
Based on 4 analysts giving stock ratings to TRDA in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for TRDA in the last 3 months.
Highest
Current US$ ५.०९
US$ २५.०० (+३९१.१६%)
Average
US$ १९.३३ (+२७९.७६%)
Lowest
US$ १०.०० (+९६.४६%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Hold
Reiterated
-
-
11/12/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Reiterated
US$ १०.००
+९६.५%
11/06/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
US$ २५.००
+३९१.२%
10/15/2026
Kostas Biliouris
Oppenheimer
Buy
Reiterated
US$ २३.००
+३५१.९%
09/03/2026
Myles Minter
William Blair
Buy
Maintained
-
-
08/05/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
US$ १७.००
+२३४%
06/05/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
05/07/2026
Yanni Souroutzidis
Cantor Fitzgerald
Buy
Initiated
-
-
04/01/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
१२.९९ लाख
८.७५ लाख
८.९८ लाख
९.०५ लाख
Cost of goods sold
३.२३ करोड
३.३१ करोड
३.५४ करोड
३.२४ करोड
Cost of revenue
३.२३ करोड
३.३१ करोड
३.५४ करोड
३.२४ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
९३.५० लाख
१.०१ करोड
१.०५ करोड
१.०२ करोड
Operating expense
९३.५० लाख
१.०१ करोड
१.०५ करोड
१.०२ करोड
Total operating expenses
४.१६ करोड
४.३२ करोड
४.५९ करोड
४.२६ करोड
Operating income
-४.०३ करोड
-४.२३ करोड
-४.५० करोड
-४.१७ करोड
Other non operating income
-
-
-
-
EBT including unusual items
-३.९१ करोड
-३.९७ करोड
-४.२७ करोड
-३.९७ करोड
EBT excluding unusual items
-३.७२ करोड
-३.९७ करोड
-४.२७ करोड
-३.९७ करोड
Income tax expense
९२.०० हजार
३८.०० हजार
३५.०० हजार
२७.०० हजार
Effective tax rate
-०.२४%
-०.१०%
-०.०८%
-०.०७%
Other operating expenses
-
-
-
-
Net income
-३.९२ करोड
-३.९७ करोड
-४.२८ करोड
-३.९७ करोड
Net profit margin
-३,०१४.९३%
-४,५३९.०९%
-४,७६२.०३%
-४,३९१.३८%
Earnings per share
-०.९४
-०.९५
-१.०१
-०.९४
Interest and investment income
३१.३६ लाख
२६.२४ लाख
२२.३५ लाख
१९.७४ लाख
Interest expense
-
-
-
-
Net interest expenses
३१.३६ लाख
२६.२४ लाख
२२.३५ लाख
१९.७४ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-३.९४ करोड
-४.१५ करोड
-४.४१ करोड
-४.१० करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू